Cancer Drug Resistance
All Journals
Search Log In
Home Articles Special Issues Volumes Webinars Videos
Cancer Drug Resistance
Search Submit
Home Articles Special Issues Volumes Webinars Videos

fig1

From:  Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer
Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer

Figure 1. Flow diagram and study design. (A) Flow diagram; (B) Study design. HER2: Human epidermal growth factor receptor 2; SJTU-BCDC: Shanghai Jiao Tong University Breast Cancer Database; TCGA: The Cancer Genome Atlas; DNA: deoxyribonucleic acid; WES: whole-exome sequencing; TILs: tumor-infiltrating lymphocytes; H&E stain: hematoxylin and eosin stain; ALN: axillary lymph node; ER: estrogen receptor; PR: progesterone receptor.

Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
Rss
© 2016-2025 OAE Publishing Inc., except certain content provided by third parties